What new achievements has Yiling Pharmaceutical made in the innovation of traditional Chinese medicine so far?

In recent years, Yiling Pharmaceutical has always adhered to the innovative development strategy of market leading and technology leading, and its innovative strength has been rapidly improved, and the output efficiency of R&D has been continuously improved. During the four years from 2020 to 2023, Yiling Pharmaceutical Company obtained four new drugs, namely, Shenyang Yanxin Tablet, Jieyu Qufan Capsule, Lianhua Qingke Tablet and Tongluo Mingmu Capsule. At the same time, in June last year, 5438+ 10, the company's exclusive innovative Chinese medicine "Tongluo Mingmu Capsule" was approved for listing in the State Administration of Pharmaceutical Products; In June last year, 5438+065438+ 10, the application for new drug registration of "Xinqitongbi Tablet" submitted by Beijing Yiling Company was officially accepted by the State Administration of Medical Supplies. At present, the company still has three innovative Chinese medicine drugs in the third phase of clinical practice. It can be predicted that Yiling Pharmaceutical will usher in the outbreak of new Chinese medicine in the next few years.